According to the Zhitong Finance App, Kangson Pharmaceutical (01681) announced its results for the year ended December 31, 2017. The group's revenue during the year was RMB 1.66 billion (same unit), an increase of 35.7% over the previous year. Gross profit was 1,228 million yuan, an increase of 34.8% over the previous year. The profit attributable to the company's equity shareholders was 396 million yuan, an increase of 28.8% over the previous year. The basic profit per share is $0.4602, and a final dividend of HK$0.1 per share is proposed.

According to the announcement, according to the product series, sales of nephrology series products increased by about 11.0% compared to last year. Among them, uremia tablets are still the group's flagship product, maintaining the leading position among modern proprietary Chinese medicines for kidney disease; although sales of medical imaging contrast agents decreased slightly by about 4.2% compared to last year, they still occupy the forefront of the domestic magnetic resonance imaging contrast agent market; sales of bone injury series products increased by about 122.6%; sales of hepatobiliary series products increased by about 99.4%; sales of hepatobiliary series products increased by about 99.4%; sales of hepatobiliary series products increased by about 195.2%; sales of hepatobiliary series products increased by about 195.2%; sales of hepatobiliary series products increased by about 195.2%; sales of hepatobiliary series products increased by about 195.2%; sales of hepatobiliary series products increased by about 195.2%; sales of maternal and child series products were added to the group's sales of over 100 million products. Sales of other pharmaceutical products increased by about 37.8%; and sales of other pharmaceutical products increased by about 79.3%.

Furthermore, the group's average gross margin was about 74%, which was only a slight decrease of 0.5 percentage points compared to 74.5% last year, mainly due to management's efforts to maintain the group's product prices and control production costs.